Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

IDEXX LABORATORIES INC /DE Director's Dealing 2021

May 20, 2021

30016_dirs_2021-05-20_e31d81d0-7a84-413a-95c0-46b42a0bd169.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IDEXX LABORATORIES INC /DE (IDXX)
CIK: 0000874716
Period of Report: 2021-05-18

Reporting Person: AYERS JONATHAN W (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-05-18 Common Stock M 7632 $79.54 Acquired 661333 Direct
2021-05-18 Common Stock S 7632 $528.0148 Disposed 653701 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-05-18 Non-Qualified Stock Option (right-to-buy) $79.54 M 7632 Disposed 2025-02-13 Common Stock (7632) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 10000 Indirect

Footnotes

F1: Represents the weighted average price of the shares sold ranging from a low of $528.00 to a high of $528.355 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F2: Grant of option to buy 74,316 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2016 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

F3: Not applicable.